The side effects of statin ads

Television advertising may drive over-diagnosis of high cholesterol and over-treatment with statins, according to a new study by Dr. Jeff Niederdeppe from Cornell University in the US and colleagues. It appears that a trip to the doctor enquiring about statins advertised on TV often leads to a prescription. The work appears online in the Journal of General Internal Medicine, published by Springer.

Coronary heart disease is the leading cause of death in the US, and high levels of LDL-cholesterol, or 'bad' cholesterol, are a major contributor. Statins have been proven to reduce LDL-cholesterol, but do they also have a role to play in the primary prevention of coronary heart disease? The jury is still out.

Statins are advertised on television with the aim of educating the population about health risks and encouraging people to seek medical advice, relevant diagnostic tests and appropriate treatment. Niederdeppe and colleagues explored whether exposure to direct-to-consumer advertising of statins was related to high cholesterol diagnosis and statin use among men and women at high, moderate, or low risk for future cardiac events.

The authors looked at how often 106,685 American adults were potentially exposed to direct-to- consumer advertising of statin drugs on national, cable and local television between 2001-2007. They also gathered data on whether participants reported being diagnosed with high cholesterol, whether or not they had taken a statin in the previous year, as well as their risk factors for coronary heart disease.

Their analyses suggest that those adults who had been exposed to statin ads were 16 to 20 percent more likely to be diagnosed with high cholesterol, and 16 to 22 percent more likely to be using statins. Interestingly, the likelihood of both a diagnosis of high cholesterol and increased statin use was driven almost exclusively by men and women at low risk for future cardiac events. Conversely, those at high risk of heart disease exposed to statin ads on TV were not more likely to be taking a statin.

The authors conclude: "Our findings raise questions about the extent to which direct-to-consumer advertising may promote over-diagnosis and over-treatment for populations where risks may outweigh potential benefits. In addition, we found no evidence of favorable associations between exposure to statins in television advertisements and statin use among those at high risk for future cardiac events."

Niederdeppe J et al (2013). Direct-to-consumer television advertising exposure, diagnosis with high cholesterol, and statin use. Journal of General Internal Medicine; DOI 10.1007/s11606-013-2379-3

Most Popular Now

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pfizer announces positive top-line results for pot…

Pfizer Inc. has announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera® (rituximab-EU), met its primary endpoint. PF-...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]